Icrucumab is a human monoclonal antibody directed against vascular endothelial growth factor receptor-1 (VEGFR-1). Icrucumab inhibits ligand-dependent phosphorylation of VEGFR-1 and downstream signaling, making icrucumab an attractive candidate for antitumor activity.